Clinical Trials Logo

Multiple Sclerosis clinical trials

View clinical trials related to Multiple Sclerosis.

Filter by:

NCT ID: NCT00492765 Completed - Multiple Sclerosis Clinical Trials

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

SIMCOMBIN
Start date: February 2006
Phase: Phase 4
Study type: Interventional

This study is to find out if there is any benefit to adding Simvastatin to Interferon-beta-1a in patients with Multiple Sclerosis.

NCT ID: NCT00492570 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

GER-009-06-AVX Early Therapy in Multiple Sclerosis

FIT
Start date: April 2006
Phase: N/A
Study type: Observational

This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.

NCT ID: NCT00492466 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies

RECOVER
Start date: March 2003
Phase: Phase 4
Study type: Interventional

This study is to find out if Interferon-beta can recover its effectiveness in patients with Multiple Sclerosis who have previously developed neutralizing antibodies to Interferon-Beta.

NCT ID: NCT00490906 Completed - Multiple Sclerosis Clinical Trials

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Start date: June 2007
Phase: N/A
Study type: Observational

The purpose of this study is to determine if certain drugs commonly used to treat multiple sclerosis have an effect on bone health.

NCT ID: NCT00489489 Completed - Multiple Sclerosis Clinical Trials

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Start date: May 2007
Phase: Phase 2
Study type: Interventional

The primary objective was to estimate the tolerability and safety of 2 doses of teriflunomide administered once daily for 24 weeks, compared with placebo, in patients with multiple sclerosis [MS] with relapses who were on a stable dose of interferon-β [IFN-β]. Secondary objectives were: - to estimate the effects of the 2 doses of teriflunomide, compared to placebo, in combination with a stable dose of IFN-β on Magnetic Resonance Imaging [MRI] parameters, relapse rate and patient-reported fatigue; - to perform pharmacokinetic analyses of the 2 doses of teriflunomide in combination with a stable dose of IFN-β.

NCT ID: NCT00488839 Completed - Multiple Sclerosis Clinical Trials

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Start date: June 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effects, both good and bad, of IPX056 on subjects and their spasticity. This study will also determine the relationship between the amount of IPX056 in blood and the effects on spasticity. Lastly, this study will determine how long IPX056 affects spasticity.

NCT ID: NCT00483847 Completed - Multiple Sclerosis Clinical Trials

TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World

TYGRIS - ROW
Start date: September 2006
Phase: N/A
Study type: Observational

The primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAEs) in participants with multiple sclerosis (MS) treated with TYSABRI (natalizumab).

NCT ID: NCT00483652 Completed - Multiple Sclerosis Clinical Trials

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Start date: May 2007
Phase: Phase 3
Study type: Interventional

The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.

NCT ID: NCT00480181 Completed - Multiple Sclerosis Clinical Trials

Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis

Start date: June 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether nabilone (Cesamet) when used as an adjunctive agent with gabapentin (Neurontin) provides significantly improved pain relief over gabapentin alone for the management of neuropathic pain in MS.

NCT ID: NCT00477113 Completed - Multiple Sclerosis Clinical Trials

TYSABRI Global Observational Program in Safety

TYGRIS
Start date: January 2007
Phase: N/A
Study type: Observational

The Primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAE) in participants with multiple sclerosis (MS) treated with Tysabri (natalizumab).